United Therapeutics down 3% over possible delay in Remodulin infusion pump
Mar. 14, 2017 4:18 PM ETUnited Therapeutics Corporation (UTHR)MDT, UTHRBy: Douglas W. House, SA News Editor1 Comment
- United Therapeutics (NASDAQ:UTHR) was under pressure today, down 3% on light volume, on a possible delay in releasing a programmable infusion pump for Remodulin (treprostinil) users.
- RBC's Michael Yee says the heightened risk comes from Medtronic's (NYSE:MDT) recall of its SynchroMed II/EL pumps due to a priming bolus issue, which it plans to fix with a software update. A year ago, the FDA rejected Medtronic's marketing application for an implantable pump to deliver Remodulin. The pulmonary arterial hypertension med faces generic competition in 2018 so a delay in offering an implantable pump option would make it more difficult for UTHR to protect sales.
- Source: Bloomberg